AIIMS Delhi Starts Covaxin Human Clinical Trials
Trials on 100 participants was held today at the All India Institute of Medical Sciences in the national capital
In a positive development, human trials for India’s first coronavirus vaccine, commenced today at the All India Institute of Medical Sciences (AIIMS), New Delhi.
Covaxin, indigenously developed in a joint effort by the Indian Council of Medical Research (ICMR) and Bharat Biotech, will be administered to 375 volunteers, of which 100 were a part of the AIIMS Delhi trials.
A total of 12 medical institutes have been identified by the ICMR as trial sites, including AIIMS Patna and PGIMS in Rohtak, Haryana. While AIIMS, Patna is monitoring the trial on a 26 year old man, PGI, Rohtak is also working with three volunteers actively. No adverse effects of the vaccine, which is in the first phase of its three phase trials, have been reported till now.
With almost 1.5 crore infections across the world and over 10 lakh cases in India alone, the success of this vaccine will bring us much needed relief.
Get the latest updates about Coronavirus only on ZEE5.